XYLYX BIO, INC.
Acellular human IPF lung extracellular matrix (ECM) substrates for physiologically-relevant in-vitro disease modeling and anti-fibrotic compound testing
- Sector
- Biotech
- Headquarters
- Brooklyn, NY
- Total capital
- $8.1M
- Federal grants
- $8.1M
- 13 awards · 2018–2025
- Rank in peer group#1 of 20
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development$968K
- Federal grantHealth and Human S · Phase II · Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation$1.5M
- Federal grantHealth and Human S · Phase II · Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development$966K
- Federal grantHealth and Human S · Phase II · Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development$370K
- Federal grantHealth and Human S · Phase II · Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development$296K
- Federal grantHealth and Human S · Phase II · Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$109K
- Federal grantHealth and Human S · Phase II · Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$961K
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$70K
- Federal grantHealth and Human S · Phase II · Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$2.1M
- Federal grantHealth and Human S · Phase II · Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$298K
- Federal grantHealth and Human S · Phase I · Biomimetic lung sealant to rapidly heal pulmonary air leaks, decrease recovery time, and reduce associated costs to the healthcare system,$224K
- Federal grantHealth and Human S · Phase I · Native cell specific microenvironments for improved cell culture$55K
- Federal grantHealth and Human S · Phase I · Fibrotic lung extracellular matrix cell culture substrate to improve predictive in vitro models of pulmonary fibrosis for accelerating drug development towards more effective treatment options$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 20 peers
Line = medianBiotech · Material
- Federal grants#1 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 9- PendingDevices And Methods For In Vitro Modeling Of Metastatic CancerUSPTOApplication 17997829
- PendingTissue-derived Matrikine Compositions And Methods ThereforUSPTOApplication 18021660
- PendingFibrosis-specific Cell Culture Substrate And Methods Of UseUSPTOApplication 17629046
Show all 9 patent records
- Devices And Methods For In Vitro Modeling Of Metastatic CancerJun 20, 2024 · Application 17997829Pending
- Tissue-derived Matrikine Compositions And Methods ThereforJan 25, 2024 · Application 18021660Pending
- Fibrosis-specific Cell Culture Substrate And Methods Of UseAug 25, 2022 · Application 17629046Pending
- Tissue-derived Matrikine Compositions And Methods ThereforApplication PCTUS2021049432Pending
- Devices And Methods For In Vitro Modeling Of Metastatic CancerApplication PCTUS2021030840Pending
- Tissue-derived Matrikine Compositions And Methods ThereforApplication 63075638Pending
- Fibrosis-specific Cell Culture Substrate And Methods Of UseApplication PCTUS2020043342Pending
- Devices And Methods For In Vitro Modeling Of Metastatic CancerApplication 63020160Pending
- Fibrosis-Specific Cell Culture Substrate and Methods of UseApplication 62877544Pending
Related companies, and why
- Neurocarrus Inc.Similar federal contract value in Biotech · null in contracts
- Jaguar Gene TherapySimilar federal contract value in Biotech · null in contracts
- Versa Integrated Solutions, Inc.Similar federal contract value in Biotech · null in contracts
- TRELLIS BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- ALLIANCE DISCOVERY, INC.Similar federal contract value in Biotech · null in contracts
- RIDGELINE THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .